-
Signature
-
/s/ Kamran Alam, Attorney-in-Fact
-
Stock symbol
-
TSHA
-
Transactions as of
-
Sep 10, 2025
-
Transactions value $
-
-$617,240
-
Form type
-
4
-
Date filed
-
9/12/2025, 04:15 PM
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Nagendran Sukumar |
President and Head of R&D, Director |
C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS |
/s/ Kamran Alam, Attorney-in-Fact |
2025-09-12 |
0001665124 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
TSHA |
Common Stock |
Options Exercise |
$28.8K |
+41.2K |
+3.53% |
$0.70 |
1.21M |
Sep 10, 2025 |
Direct |
|
| transaction |
TSHA |
Common Stock |
Sale |
-$646K |
-200K |
-16.58% |
$3.23 |
1.01M |
Sep 10, 2025 |
Direct |
F1, F2 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
TSHA |
Employee Stock Option (right to buy) |
Options Exercise |
$0 |
-41.2K |
-12.32% |
$0.00 |
293K |
Sep 10, 2025 |
Common Stock |
41.2K |
$0.70 |
Direct |
F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: